Healthcare Equipment and Supplies
Company Overview of TearScience, Inc.
TearScience, Inc. is a medical device company that engages in identifying, diagnosing, and treating meibomian gland disease (MGD), which is the cause of dry eye. The company focuses on the early detection and treatment of prevalent, chronic, and progressive MGD. It develops LipiFlow Activator, a single-use sterile device that delivers automated therapeutic energies to each meibomian gland while protecting the delicate structures of the patient’s eye; and LipiScan, a gland imager that allows eye care professionals to evaluate meibomian glands in practices. The company was formerly known as Kolis Scientific, Inc. and changed its name to TearScience, Inc. in July 2005. TearScience, Inc. was fou...
5151 McCrimmon Parkway
Morrisville, NC 27560
Founded in 2005
Key Executives for TearScience, Inc.
Chief Executive Officer and President
Co-Founder and Chief Technical Officer
Vice President of R & D, Manufacturing & Service
Vice President of Marketing & Market Development
Compensation as of Fiscal Year 2017.
TearScience, Inc. Key Developments
TearScience Introduces LipiFlow® Activator II
May 4 17
TearScience announced the release of the LipiFlow Activator II treatment disposable. The newly released disposable maintains the same level of quality and efficacy as the original Activator. LipiFlow's Activator consists of the scleral lens heating surface, the shield structure and the pulsation bladders, all of which directly interface with the patient oculus. The Activator II meets the same standard for sterility as the original Activator. Activator II is used with a separate, semi-permanent cable, which remains connected to the LipiFlow Console. The LipiFlow System now includes a reusable cable that reduces waste. With roughly five million tons of institutional medical waste being dumped in US landfills each year, TearScience to introduce this new, waste-reducing Activator II, which is compatible with existing LipiFlow systems. LipiFlow has consistently demonstrated superior efficacy in more than 30 peer reviewed studies, now having shown sustained effect of increased mean meibomian gland secretions and improved mean dry eye symptoms from a single application. Increased recognition of the important role MGD plays in compromising the ocular surface and of new accessible pricing from TearScience is resulting in a transformation of patient care and renewed practice growth.
TearScience Names Edward J. Holland to Board of Directors
Aug 8 16
TearScience announced the addition of Edward J. Holland, MD, to its board of directors. Dr. Holland is a leader in the field of Cornea and Ocular Surface Health.
TearScience, Inc. Introduces LipiScan
May 5 16
TearScience announced the release of LipiScan, the first and only dedicated high definition (HD) gland imager that allows eye care professionals (ECPs) to efficiently evaluate meibomian glands in busy practices. The new rapid imager was created with end users in mind. Fast and intuitive, LipiScan harnesses patented dynamic meibomian imaging (DMI) technology to produce high definition images of meibomian glands. LipiScan allows ECPs to assess meibomian gland structure during routine workups in any practice setting. The introduction of LipiScan will allow busy practices to efficiently integrate assessment of meibomian glands and do so at an affordable price. MGD is a prevalent chronic, obstructive and progressive disease that impacts the tear film, visual performance and ocular comfort. LipiFlow treatment for MGD is supported by significant science. A review of 31 sponsored and unsponsored peer-reviewed reports demonstrated that a single LipiFlow treatment typically improves mean meibomian gland secretions while reducing mean patient-reported symptom scores over sustained periods.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|